Jefferies Maintains Kezar Life Sciences(KZR.US) With Buy Rating, Cuts Target Price to $18
Kezar Life Sciences: Promising AIH Phase II Results and Strategic FDA Engagement Justify Buy Rating
Analysts' Opinions Are Mixed on These Healthcare Stocks: Roche Holding AG (OtherRHHVF), Kezar Life Sciences (KZR) and Axsome Therapeutics (AXSM)
TD Cowen Maintains Kezar Life Sciences(KZR.US) With Buy Rating
William Blair Maintains Kezar Life Sciences(KZR.US) With Buy Rating
TD Cowen Maintains Kezar Life Sciences(KZR.US) With Buy Rating
William Blair Upgrades Kezar Life Sciences(KZR.US) to Buy Rating
William Blair Maintains Kezar Life Sciences(KZR.US) With Hold Rating
Wells Fargo Maintains Kezar Life Sciences(KZR.US) With Hold Rating, Cuts Target Price to $9
H.C. Wainwright Maintains Kezar Life Sciences(KZR.US) With Hold Rating
Kezar Life Sciences Is Maintained at Equal-Weight by Wells Fargo
Kezar Life Sciences Analyst Ratings
Wells Fargo Maintains Kezar Life Sciences(KZR.US) With Hold Rating, Cuts Target Price to $11
TD Cowen Maintains Kezar Life Sciences(KZR.US) With Buy Rating
Kezar Life Sciences (KZR) Receives a Buy From TD Cowen
Kezar Life Sciences Analyst Ratings
H.C. Wainwright Maintains Kezar Life Sciences(KZR.US) With Hold Rating
H.C. Wainwright Sticks to Its Hold Rating for Kezar Life Sciences (KZR)
H.C. Wainwright Maintains Kezar Life Sciences(KZR.US) With Hold Rating
Kezar Life Sciences Analyst Ratings